(BTMD) biote - Ratings and Ratios

Biote Corp (NASDAQ:BTMD) is a leader in the hormone optimization sector, focusing on practice-building solutions for healthcare providers. The company specializes in bioidentical hormone replacement therapy (BHRT) using pellet implantation, addressing hormonal imbalances in both men and women. Its Biote Method platform provides a suite of tools and resources for practitioners, including education, training, and certification programs, as well as practice management and inventory software. This end-to-end platform streamlines operations for healthcare providers, enabling them to efficiently manage hormone optimization treatments.

Biote Corp also offers a range of products, including dietary supplements under the Biote brand and sterile pellet insertion kits used in hormone replacement therapies. These products are designed to support overall patient health and complement the companys BHRT solutions. Founded in 2012 and headquartered in Irving, Texas, Biote Corp has established itself as a key player in the hormone optimization space, with a strong focus on practitioner training and support.

Looking ahead, the companys stock is expected to show volatility in the next three months, influenced by its current technical and fundamental trends. With a last price of 4.37 and a 20-day average volume of 175,053, BTMD is trading below its 20-day, 50-day, and 200-day moving averages, which stand at 4.71, 5.41, and 6.09, respectively. This indicates potential bearish momentum. The stocks ATR of 0.30 suggests moderate price movement.

From a fundamental perspective, Biote Corps market cap of 236.85M USD and forward P/E of 7.13 indicate potential undervaluation, as the forward P/E is lower than the current P/E of 14.97. However, the negative return on equity (RoE) of -7.92 raises concerns about profitability. The price-to-book ratio of 2.96 and price-to-sales ratio of 1.23 suggest the stock is trading at a premium relative to its book value and revenue.